Leerink Partnrs Comments on Larimar Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Larimar Therapeutics in a research report issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park anticipates that the company will post earnings of ($0.25) per share for the quarter. Leerink Partnrs currently has […]
More Stories
Vishal Sanghavi, Founder & CEO, JEH Aerospace, interviewing Atul Arya, Founder & CEO, Blackstraw AI
On why AI fails in production, what it actually takes to scale, and the work most companies avoid. Vishal Sanghavi...
How a Business Internet Provider Keeps Small Companies Connected
Small companies depend on internet access for payments, cloud applications, customer calls, file transfers, and daily coordination. A short outage...
How a Mortgage Marketing Agency Drives Leads for Lenders Online
Mortgage lenders compete for borrowers, who first research rates, loan types, and local providers online before contacting anyone. Visibility depends...
US Signs Critical Minerals, Energy, Technology Deals With Finland, Hungary
By Victoria Friedman The United States has signed critical mineral, energy, and technology deals with Finland and Hungary, strengthening economic...
Israel Heads for Coalition Talks After Election Deadlock
By Evgenia Filimianova Final Israeli election results showed that neither Prime Minister Benjamin Netanyahu nor his main rival, Gadi Eisenkot,...
Nasdaq Falls More Than 2 Percent as Amazon, Intel Earnings Weigh on Markets
By Andrew Moran The tech-heavy Nasdaq Composite Index fell more than 2 percent as disappointing results from Amazon and weak...